Adamis Pharmaceuticals Gets FDA Approval for Zimhi Injection Product
October 18 2021 - 7:10AM
Dow Jones News
By Chris Wack
Adamis Pharmaceuticals Corp. said the U.S. Food and Drug
Administration has approved its Zimhi naloxone HCL injection 5
mg/0.5 mL product.
Adamis said Zimhi is a high-dose naloxone injection product
FDA-approved for use in the treatment of opioid overdose.
Naloxone is an opioid antagonist and is generally considered the
drug of choice for immediate administration for opioid overdose. It
works by blocking or reversing the effects of the opioid, including
extreme drowsiness, slowed breathing, or loss of consciousness,
Adamis said.
The company said it is preparing for the full commercial launch
of Zimhi in the first quarter of 2022.
Adamis shares were up 21% to $1.35 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 18, 2021 07:55 ET (11:55 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.